

IN THE CLAIMS

Claims 1-20 (canceled)

21. (currently amended) A method of treating in-stent restenosis, a reperfusion injury, an infectious coronary syndrome, an inflammatory coronary syndrome, dilated cardiomyopathy, viral myocarditis or a reperfusion injury comprising implanting ~~the a~~ a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~of claim 18~~ in a patient in need thereof.

22. (previously presented): The method of claim 21, wherein in-stent restenosis is treated.

Claims 23-31 (canceled)

32. (currently amended) A method of treating reperfusion injuries comprising implanting ~~the stent of claim 18~~ a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions in a patient in need thereof.

33. (currently amended) A method of treating an infectious coronary syndrome comprising implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 18~~ in a patient in need thereof.

34. (currently amended) A method of treating an infectious coronary syndrome comprising implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions

~~the stent of claim 19~~ in a patient in need thereof, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

35. (currently amended) A method of treating an inflammatory coronary syndrome comprising implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 18~~ in a patient in need thereof.

36. (currently amended) A method of preventing an inflammatory coronary syndrome comprising implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 18~~ in a patient in need thereof.

37 (currently amended) A method of treating dilated cardiomyopathy comprising implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 18~~ in a patient in need thereof.

38. (currently amended) A method of treating dilated cardiomyopathy comprising implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 19~~ in a patient in need thereof, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

39. (currently amended) A method of treating viral myocarditis by implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 18~~ in a patient in need thereof.

40. (currently amended) A method of treating viral myocarditis by implanting a stent coated with 3-deazaadenosine or an analog of 3-deazaadenosine selected from the group consisting of a salt of 3-deazaadenosine and a precursor of 3-deazaadenosine which degrades to 3-deazaadenosine in a body under physiological conditions ~~the stent of claim 19~~ in a patient in need thereof, wherein said analog of deazaadenosine is selected from the group consisting of 3-deazaadenosine-3'-monophosphoric acid, 3-deazaadenosine-3'5'-cyclophosphate and 3-deazaadenosine-5'-diphosphoric acid.

41. (previously presented)A method according to claim 21, wherein the method comprises treating in-stent restenosis, an inflammatory coronary syndrome, dilated cardiomyopathy, or viral myocarditis.

42. (previously presented)A method according to claim 21, wherein the method comprises treating in-stent restenosis, a reperfusion injury, an inflammatory coronary syndrome, or dilated cardiomyopathy.

43. (previously presented)The method of claim 41, wherein in-stent restenosis or viral myocarditis is treated.

44. (previously presented)The method of claim 42, wherein a reperfusion injury or an inflammatory coronary syndrome is treated.